Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ENTX vs PLUR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–3 Matrix Metrics)

ENTX Overall Winner 6-Pillar Tally: ENTX 3 – 2 PLUR (1 Tie) Matrix Metrics: ENTX 6 – 3 PLUR

As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 53.5/100 (HOLD) at $3.01 (N/M Forward P/E, 0.0% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin).

  • Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. PLUR 28.8/100 SELL) and 1.07β · 45% Vol risk profile, whereas PLUR leads top-line expansion (-15.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ENTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.8); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTX vs PLUR
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.01
-0.33% 1D
Market Cap $541.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.07β · 45% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 35.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.8 · SMA20: $3.09 · SMA50: $2.90
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
TTM Revenue $1.0M
Forward P/E 3.6x
Beta / 30D Vol 0.80β · 102% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $1.14 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (ENTX 3 – 2 PLUR)

Columns: Metric · ENTX · PLUR
1. Valuation Multiples PLUR
Forward P/E N/M 3.6x
Trailing P/E N/M 3.6x
PEG Ratio N/M N/M
EV / Revenue N/M 44.6x
2. Growth & Scale PLUR
Revenue Growth (YoY) -100.0% -15.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.0M
Market Cap $541.6M $15.1M
3. Profitability & Quality ENTX
Gross Margin N/A 44.6%
Operating Margin 0.0% -2454.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -20.3% -1022.0%
4. Balance Sheet & Cash Flow ENTX
Cash Generation (TTM) -$16M -$22M
Cash Flow Margin N/A N/A
Net Cash / Leverage $265M Net Cash $30M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 113.8% (32nd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTX (6) vs PLUR (3)
Institutional Metric ENTX PLUR Criterion Row Edge
Market Capitalization
Scale
$541.6M $15.1M Larger Scale ENTX
Trailing P/E Ratio
Valuation
N/M 3.6x Lower Multiple PLUR
Forward P/E Ratio
Valuation
N/M 3.6x Lower Multiple PLUR
Revenue Growth (YoY)
Growth
-100.0% -15.8% Higher Growth PLUR
Operating Margin (TTM)
Profitability
0.0% -2454.5% Higher Margin ENTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-20.3% -1022.0% Higher ROE ENTX
52-Week Range Position
Momentum
64% ($1–$4) 2% ($1–$5) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
1.07β · 45% Vol 0.80β · 102% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
53.5 / 100 (HOLD) 28.8 / 100 (SELL) Higher Composite ENTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 44.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 44.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M ($265M Net Cash) -$22M ($30M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLUR +8.71 pp
ENTX: +2.38% · PLUR: +11.09%
3M Horizon ENTX +43.12 pp
ENTX: -3.22% · PLUR: -46.34%
6M Horizon ENTX +199.53 pp
ENTX: +137.01% · PLUR: -62.52%
1Y Horizon ENTX +86.6 pp
ENTX: +11.07% · PLUR: -75.53%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENTX Revenue PLUR Revenue ENTX Op. Margin PLUR Op. Margin Margin Leader
FY2019 N/A $0M N/A -65800.0% PLUR
FY2020 $0M $0M -3059.7% -128156.5% ENTX
FY2021 $0M N/A -2139.6% N/A ENTX
FY2022 $0M $0M -9714.2% -17774.8% ENTX
FY2023 N/A $0M N/A -9493.4% PLUR
FY2024 $0M $0M -5295.6% -6796.9% ENTX
FY2025 $0M $0M -27450.0% -1659.9% PLUR
FY2026 N/A $0M N/A -2454.5% PLUR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTX CONSOLIDATION
80d in phase · OBV NEUTRAL
Current IV 113.8%
IV Percentile 32nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PLUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PLUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $541.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PLUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.1M market capitalization and -2454.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTX vs PLUR Key Questions & Quantitative Answers

As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 53.5/100 (HOLD) at $3.01 (N/M Forward P/E, 0.0% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin). Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. PLUR 28.8/100 SELL) and 1.07β · 45% Vol risk profile, whereas PLUR leads top-line expansion (-15.8% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ENTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.8); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PLUR leads the Growth & Scale pillar: ENTX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PLUR at -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), ENTX cumulative revenue shifted N/A while PLUR shifted N/A. In operating R&D and SG&A reinvestment, ENTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PLUR.

PLUR screens cheaper on headline valuation multiples. ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTX (-20.3% ROE) versus PLUR (-1022.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTX carries 113.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 45% Vol realized risk). By comparison, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.